Reuters logo
4 个月前
BRIEF-Compugen ltd selects of com902 as lead clinical antibody candidate for immuno-oncology program
2017年3月28日 / 上午11点12分 / 4 个月前

BRIEF-Compugen ltd selects of com902 as lead clinical antibody candidate for immuno-oncology program

1 分钟阅读

March 28 (Reuters) - Compugen Ltd:

* Compugen Ltd - selection of com902 as lead clinical antibody candidate for cgen-15137/tigit t cell checkpoint inhibitor program in immuno-oncology Source text:(bit.ly/2oceUEM) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below